A report by Lloyd's Emerging Risk Team Synthetic Biology: influencing development has just been published. Drawing upon a number of sources, including the summary of the Royal Society's synthetic biology discussion meeting, it highlights both the opportunities and concerns this field raises. It concludes that 'insurers should consider whether they wish liability products to be exposed to large scale aggregating events and, if not, whether limits should imposed or other policy amendments made. Most of all, we should take part in a broad debate on the use of this new technology before it becomes embedded.'
No comments:
Post a Comment